| Time | Stream A | Stream B |
|---|---|---|
| 9:00 | Registration and coffee | |
| 9:30 |
Opening remarks from the chairs
|
|
| 9:40 |
Translational Research: A Strategy for Target Validation to Reduce Risk and Maximise Opportunities
|
|
| 10:20 |
Defining “Proof-of-Concept” within Various Organisation Types in Context of Evolving Development Paradigms; What is it and what should it be?
|
|
| 11:00 | Networking coffee break | |
| 11:20 |
Applicability and Effective Translation of Animal Biomarker Models to Man
|
|
| 12:00 |
Reviewing the FDA's Critical Path Initiative 2004: One year on
|
|
| 12:40 | Lunch | |
| 14:00 |
Assessing the Main Causes of Failure in Early Clinical Trials
|
|
| 14:40 | Panel discussion: Biomarkers |
|
| 15:20 | Networking coffee break | |
| Stream A – Biomarkers I | Stream B – Biomarkers II | |
| 15:40 |
Clinical Response Prediction: a new approach to the optimisation of development from preclinical to Phase II/III
|
OMICS for the Identification of Biomarkers: Latest Developments from Industry
|
| 16:20 |
Appetite, Anxiety and Pain – Pharmacodynamic Models Searching for a Molecule
|
Case Study: How “Viral Load” became a Surrogate – Issues Faced in the Search for Viable Biomarkers for the Early Approval of Anti-HIV Therapies |
| 18:00 |
Closing remarks from the Chairs |
|
| 18:10 | End of day one | |